These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21155605)

  • 21. Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.
    Forster M; Chaikuad A; Dimitrov T; Döring E; Holstein J; Berger BT; Gehringer M; Ghoreschi K; Müller S; Knapp S; Laufer SA
    J Med Chem; 2018 Jun; 61(12):5350-5366. PubMed ID: 29852068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
    Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
    Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
    Norman P
    Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
    Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
    Clark MP; George KM; Bookland RG; Chen J; Laughlin SK; Thakur KD; Lee W; Davis JR; Cabrera EJ; Brugel TA; VanRens JC; Laufersweiler MJ; Maier JA; Sabat MP; Golebiowski A; Easwaran V; Webster ME; De B; Zhang G
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1250-3. PubMed ID: 17189692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.
    Jaime-Figueroa S; De Vicente J; Hermann J; Jahangir A; Jin S; Kuglstatter A; Lynch SM; Menke J; Niu L; Patel V; Shao A; Soth M; Vu MD; Yee C
    Bioorg Med Chem Lett; 2013 May; 23(9):2522-6. PubMed ID: 23541670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.
    Yoshida H; Kimura A; Fukaya T; Sekiya T; Morita R; Shichita T; Inoue H; Yoshimura A
    Biochem Biophys Res Commun; 2012 Feb; 418(2):234-40. PubMed ID: 22252297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
    de Vicente J; Lemoine R; Bartlett M; Hermann JC; Hekmat-Nejad M; Henningsen R; Jin S; Kuglstatter A; Li H; Lovey AJ; Menke J; Niu L; Patel V; Petersen A; Setti L; Shao A; Tivitmahaisoon P; Vu MD; Soth M
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4969-75. PubMed ID: 25262541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
    Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
    Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
    Yu V; Pistillo J; Archibeque I; Han Lee J; Sun BC; Schenkel LB; Geuns-Meyer S; Liu L; Emkey R
    Exp Hematol; 2013 May; 41(5):491-500. PubMed ID: 23340136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
    Flanagan ME; Blumenkopf TA; Brissette WH; Brown MF; Casavant JM; Shang-Poa C; Doty JL; Elliott EA; Fisher MB; Hines M; Kent C; Kudlacz EM; Lillie BM; Magnuson KS; McCurdy SP; Munchhof MJ; Perry BD; Sawyer PS; Strelevitz TJ; Subramanyam C; Sun J; Whipple DA; Changelian PS
    J Med Chem; 2010 Dec; 53(24):8468-84. PubMed ID: 21105711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
    Chrencik JE; Patny A; Leung IK; Korniski B; Emmons TL; Hall T; Weinberg RA; Gormley JA; Williams JM; Day JE; Hirsch JL; Kiefer JR; Leone JW; Fischer HD; Sommers CD; Huang HC; Jacobsen EJ; Tenbrink RE; Tomasselli AG; Benson TE
    J Mol Biol; 2010 Jul; 400(3):413-33. PubMed ID: 20478313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.
    Lin TH; Hegen M; Quadros E; Nickerson-Nutter CL; Appell KC; Cole AG; Shao Y; Tam S; Ohlmeyer M; Wang B; Goodwin DG; Kimble EF; Quintero J; Gao M; Symanowicz P; Wrocklage C; Lussier J; Schelling SH; Hewet AG; Xuan D; Krykbaev R; Togias J; Xu X; Harrison R; Mansour T; Collins M; Clark JD; Webb ML; Seidl KJ
    Arthritis Rheum; 2010 Aug; 62(8):2283-93. PubMed ID: 20506481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
    Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
    J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
    Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G
    J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
    Rashid S; Bibi N; Parveen Z; Shafique S
    J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
    Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
    Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.
    Ito M; Yamazaki S; Yamagami K; Kuno M; Morita Y; Okuma K; Nakamura K; Chida N; Inami M; Inoue T; Shirakami S; Higashi Y
    J Pharmacol Sci; 2017 Jan; 133(1):25-33. PubMed ID: 28117214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
    Zak M; Mendonca R; Balazs M; Barrett K; Bergeron P; Blair WS; Chang C; Deshmukh G; Devoss J; Dragovich PS; Eigenbrot C; Ghilardi N; Gibbons P; Gradl S; Hamman C; Hanan EJ; Harstad E; Hewitt PR; Hurley CA; Jin T; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Kulagowski JJ; Labadie S; Liao J; Liimatta M; Lin Z; Lupardus PJ; Maxey RJ; Murray JM; Pulk R; Rodriguez M; Savage S; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Xiao L; Xiao Y
    J Med Chem; 2012 Jul; 55(13):6176-93. PubMed ID: 22698084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.